pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Columvi
drug · antibody
save

glofitamab

Marketedupdated 6mo ago
by F. Hoffmann-La Roche Ltd🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • drugCOLUMVI12 co-mentions · 3 sources
  • tagApproval12 co-mentions · 3 sources
  • companyGenentech Inc6 co-mentions · 3 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and diffuse large b-cell lymphoma and 6 investigational indications.

indications

investigational
DLBCL

targets

B-lymphocyte antigen CD20T cell surface glycoprotein CD3

all catalysts(3)

approval · 3
Jun 15, 2023
approval
3y ago
COLUMVI (GLOFITAMAB-GXBM) — FDA approval
glofitamab
→
Jun 9, 2025
approval
1y ago
COLUMVI (GLOFITAMAB-GXBM) — FDA approval
glofitamab
→
Oct 27, 2025
approval
1y ago
COLUMVI (GLOFITAMAB-GXBM) — FDA approval
glofitamab
→

Trials studying glofitamab

  • —An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphomarecruitingn=300
  • phase2Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCLrecruitingn=38
  • phase2An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphomaactive not recruitingn=211
  • phase3A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphomaactive not recruitingn=270
  • phase2A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphomaactive not recruitingn=46
  • phase2A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphomarecruitingn=40
  • phase2MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)recruitingn=178
  • phase3A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphomarecruitingn=182

News(7)

  • Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosion
    Bracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.
    biospace · 28d ago
  • Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
    Novartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cyto…
    biospace · 1mo ago
  • ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
    When recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.
    fiercebiotech · 1mo ago
  • Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
    Genentech's agreement with Earendil Labs came the same day its parent company, Roche, inked a cardiometabolic and renal deal with Atavistik Bio for up to $2 billion.
    biospace · 1mo ago
  • Roche bets up to $1B to advance next-gen bispecifics with Dualitas
    The partners will focus R&D efforts on immunological and inflammatory conditions using Dualitas’ DualScreen Bispecific Discovery Engine platform.
    biospace · 2mo ago
  • Roche, Dualitas team up to find bispecific drugs for immune diseases
    Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments.
    biopharma_dive · 2mo ago
  • Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
    Roche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseases.
    fiercebiotech · 2mo ago
brand
Columvi
trade names
Columvi
generic
glofitamab-gxbm
MOA
B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent
indication
Mantle Cell Lymphoma
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?